The angiotensin-converting-enzyme 2 is a crucial receptor as it enables SARS-CoV-2 entry into the cell. This receptor also plays an important function in the human body primarily acting as a regulator of the renin-angiotensin system.
Scientists have synthesized human recombinant soluble ACE2- hrsACE2. The hrsACE2 can bind to the viral spike glycoprotein and in turn neutralize SARS-CoV-2. It can also minimize the injury to multiple organs because of unrelenting renin-angiotensin system hyperactivation and augmented angiotensin II concentration.
The hrsACE2 was recently used on a COVID-19 positive 45-year-old woman. Her clinical condition failed to improve despite treatment. Her respiratory condition was also markedly deteriorating. She received hrsACE2 on compassionate grounds and following the first injection, a marked reduction in angiotensin II followed by a reduction in cytokine, C-reactive protein and ferritin levels was noted.
Researchers have noted that hrsACE2 can decrease SARS-CoV-2 load by a factor of 1000-5000 in cell culture experiments. The hrs ACE2 has been tested in 89 patients and has shown a good safety profile.
To know more about origin, virology of COVID-19, Click here
To know more about emerging themes in COVID-19, Click here
To know more about how WhiteCoats can help you in your professional advancement, visit www.whitecoats.com
Want to set up an online consultation for your practice, Click here